ATE315645T1 - Dns oder gene, die an der parkinsonschen krankheit beteiligt sind - Google Patents

Dns oder gene, die an der parkinsonschen krankheit beteiligt sind

Info

Publication number
ATE315645T1
ATE315645T1 AT99902859T AT99902859T ATE315645T1 AT E315645 T1 ATE315645 T1 AT E315645T1 AT 99902859 T AT99902859 T AT 99902859T AT 99902859 T AT99902859 T AT 99902859T AT E315645 T1 ATE315645 T1 AT E315645T1
Authority
AT
Austria
Prior art keywords
disease
parkinson
dna
genes involved
sequence
Prior art date
Application number
AT99902859T
Other languages
English (en)
Inventor
Nobuyoshi Shimizu
Yoshikuni Mizuno
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Application granted granted Critical
Publication of ATE315645T1 publication Critical patent/ATE315645T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT99902859T 1998-02-09 1999-02-09 Dns oder gene, die an der parkinsonschen krankheit beteiligt sind ATE315645T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2753198 1998-02-09

Publications (1)

Publication Number Publication Date
ATE315645T1 true ATE315645T1 (de) 2006-02-15

Family

ID=12223704

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99902859T ATE315645T1 (de) 1998-02-09 1999-02-09 Dns oder gene, die an der parkinsonschen krankheit beteiligt sind

Country Status (10)

Country Link
US (2) US6716621B1 (de)
EP (1) EP1063294B1 (de)
JP (1) JP4430815B2 (de)
AT (1) ATE315645T1 (de)
AU (1) AU2299999A (de)
CA (1) CA2320220C (de)
DE (2) DE1063294T1 (de)
DK (1) DK1063294T3 (de)
ES (1) ES2257029T3 (de)
WO (1) WO1999040191A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775984B1 (fr) * 1998-03-11 2006-09-15 Bioscreen Therapeutics Sa Criblage differentiel qualitatif
DK1063294T3 (da) * 1998-02-09 2006-05-22 Boehringer Ingelheim Int DNA'er eller gener der deltager i Parkinsons sygdom
WO2000031253A2 (fr) 1998-11-19 2000-06-02 Aventis Pharma S.A. Mutations du gene de la parkine, compositions, methodes et utilisations
CA2872581C (fr) 1998-11-19 2018-04-10 Aventis Pharma S.A. Mutations du gene de la parkine, compositions, methodes et utilisations
EP1081225A1 (de) * 1999-08-30 2001-03-07 Biofrontera Pharmaceuticals GmbH Transgenes Tiermodel für neurodegenerative Erkrankungen
EP1262557B1 (de) * 2000-02-24 2006-10-18 Boehringer Ingelheim International GmbH Das parkin-protein als ubiquitinligase
WO2001070944A2 (de) * 2000-03-22 2001-09-27 Aventis Pharma Deutschland Gmbh Nematoden als modellorganismen zur untersuchung neurodegenerativer erkrankungen und insbesonder der parkinsonschen erkrankung, verwendungen und verfahren zum auffinden von substanzen und genen, die bei der behandlung solcher erfrankungen eingesetz werden können, sowie identifizierung eines nematodengens.
US7070940B2 (en) * 2002-07-18 2006-07-04 Aventis Pharma S.A. Method for determining the ability of a compound to modify the interaction between parkin and the p38 protein
TW200509968A (en) * 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8697082B2 (en) 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
CA2677231C (en) 2007-01-31 2015-11-24 Elan Pharmaceuticals, Inc. Assays for modulators of parkin activity using novel substrates
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
PL2118300T3 (pl) 2007-02-23 2015-11-30 Prothena Biosciences Ltd Zapobieganie i leczenie synukleinopatii i amyloidozy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1063294T3 (da) * 1998-02-09 2006-05-22 Boehringer Ingelheim Int DNA'er eller gener der deltager i Parkinsons sygdom

Also Published As

Publication number Publication date
CA2320220A1 (en) 1999-08-12
EP1063294B1 (de) 2006-01-11
DE69929417T2 (de) 2006-08-03
AU2299999A (en) 1999-08-23
EP1063294A4 (de) 2002-01-16
DE1063294T1 (de) 2003-06-26
US20050003385A1 (en) 2005-01-06
JP4430815B2 (ja) 2010-03-10
ES2257029T3 (es) 2006-07-16
US6716621B1 (en) 2004-04-06
WO1999040191A1 (en) 1999-08-12
EP1063294A1 (de) 2000-12-27
DK1063294T3 (da) 2006-05-22
DE69929417D1 (de) 2006-04-06
CA2320220C (en) 2011-08-02

Similar Documents

Publication Publication Date Title
DE69929417D1 (de) Dns oder gene, die an der parkinsonschen krankheit beteiligt sind
DK1013661T3 (da) 2'-O,4'-metylen bicyklonukleosid
DE69840748D1 (de) Verfahren zur zubereitung von antisense oligonukleotiden
EP0251786A3 (en) Alkynylamino-nucleotides
DE69920477D1 (de) 2'-modifizierte oligonucleotide mit rns wirkung, die konformell eingeschränkt sind
ATE374836T1 (de) Massenmarkierte hybridisierungssonden
DE69719220D1 (de) Neue nucleotidanaloga
DE69806003D1 (de) Dna polymerasen, die verbesserte fähigkeiten zum einbau markierter nukleotide besitzen
BR9705813B1 (pt) processo para produzir éster nucleosìdeo-5'-fosfato, fosfatase ácida mutante, gene isolado codificando fosfatase ácida mutante.
DE69825253D1 (de) Verfahren für die herstellung von 1,1,1,3,3-pentafluorpropen und 2-chlor-pentafluorpropen
BR9912951A (pt) Método de fabricação de nucleotìdoes de 1,3-oxatiolano
DE69736840D1 (de) Synthese von nukleosiden und polynukleotiden
ATE193733T1 (de) Stahl für die herstellung von teilbaren maschinenteilen und maschinenteile, hergestellt aus diesen stahl
WO2001000661A3 (en) Carnitine carrier related protein-1
FI885346L (fi) Ergolinderivat, som foerhindrar parkinsons sjukdom.
ATE401403T1 (de) Nukleotidsequenzen, die an erhöhung oder verringerung von der ovulationsgeschwindigkeit in säugertieren beteiligt sind
NO995858D0 (no) Ny klasse kationiske nukleinsyre-overföringsmidler
ATE270331T1 (de) Rezeptor und dafür kodierendes nukleinsäuremolekül
WO1999066077A3 (en) Methods for the detection of nucleic acids
WO1998022586A3 (en) HUMAN POLYHOMEOTIC 2 (hph2) ACTS AS A TUMOR SUPPRESSOR
BR9800714B1 (pt) processo de pelotização de minério.
DE60238915D1 (de) Werkzeug zur herstellung dekorativer muster auf einem beschichtungsmaterial
DE3851045D1 (de) Träger für DNS-Hybridisierung.
BR9901948B1 (pt) processo de curtimento de couros com compostos carbonÍlicos.
DE59509882D1 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1063294

Country of ref document: EP